UNITED STATES
                   SECURITIES AND EXCHANGE COMMISSION
                         WASHINGTON, D.C.  20549


                               FORM 12b-25

                       NOTIFICATION OF LATE FILING

(CHECK ONE):/ /Form 10-K/ /Form 20-F/ /Form 11-K/X/Form 10-Q/ /Form N-SAR

                 For Period Ended:   September 30, 2002
                                   -------------------------------

                   /  / Transition Report on Form 10-K
                   /  / Transition Report on Form 20-F
                   /  / Transition Report on Form 11-K
                   /  / Transition Report on Form 10-Q
                   /  / Transition Report on Form N-SAR
                  For the Transition Period Ended:
                                                  --------------------
- -----------------------------------------------------------------------

READ INSTRUCTION (ON BACK PAGE) BEFORE PREPARING FORM, PLEASE PRINT OR
TYPE.  NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE
COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

- -----------------------------------------------------------------------

If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:

- -----------------------------------------------------------------------

PART I -- REGISTRANT INFORMATION
          AMERIMMUNE PHARMACEUTICALS, INC.
- -----------------------------------------------------------------------
Full Name of Registrant

          N/A
- -----------------------------------------------------------------------
Former Name if Applicable

          2325 Renaissance Drive
- -----------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)

          Las Vegas, Nevada  89119
- -----------------------------------------------------------------------
City, State and Zip Code


PART II -- RULES 12b-25(b) AND (c)


If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12B-25(b), the
following should be completed.  (check box if appropriate)

/X/  (a)  The reasons described in reasonable detail in Part III of this
          form could not be eliminated without unreasonable effort or
          expense;
/X/  (b)  The subject annual report, semi-annual report, transition
          report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion
          thereof, will be filed on or before the fifteenth calendar day
          following the prescribed due date; or the subject quarterly
          report of transition report on Form 10-Q, or portion thereof
          will be filed on or before the fifth calendar day following the
          prescribed due date; and
/ /  (c)  The accountant's statement or other exhibit required by Rule
          12B-25(c) has been attached if applicable.

PART III -- NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K,
10-Q, N-SAR, or the transition report or portion thereof, could not be
filed within the prescribed time period.

The Registrant requires more time in order to restate the 3-31-02 Form
10-KSB for additional accrual of expenses and make corresponding changes
in the 9-30-02 Form 10-QSB.

                                          (ATTACH EXTRA SHEETS IF NEEDED)

PART IV -- OTHER INFORMATION

(1)  Name and telephone number of person to contact in regard to this
     notification

          Kenneth M. Collins            702            798-6800
     --------------------------    ------------   -------------------
               (Name)              (Area Code)    (Telephone Number)

(2)  Have all other periodic reports required under Section 13 or 15(d)
     of the Securities Exchange Act of 1934 or Section 80 of the
     Investment Company Act of 1940 during the preceding 12 months or for
     such shorter period that the Registrant was required to file such
     report(s) been filed?  If answer is no, identify report(s).
                                                           /X/Yes   / /No

- -------------------------------------------------------------------

(3)  Is it anticipated that any significant change in results of
     operations from the corresponding period for the last fiscal year
     will be reflected by the earnings statements to be included in the
     subject report or portion thereof?                    / /Yes   /X/No




     If so, attach an explanation of the anticipated change, both
     narratively and quantitatively, and, if appropriate, state the
     reasons why a reasonable estimate of the results cannot be made:

     -------------------------------------------------------------------

                    AMERIMMUNE PHARMACEUTICALS, INC.
                -----------------------------------------
              (Name of Registrant as Specified in Charter)

     has caused this notification to be signed on its behalf by the
     undersigned hereunto duly authorized.

     Date: November 14, 2002            By: /s/ Kenneth M. Collins
          -----------------------          ------------------------------


   -----------------------------ATTENTION-----------------------------
   INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL
                CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001)
   -------------------------------------------------------------------